Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.59 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | RXRG | P48443 | 1/20 | 0.43 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8689909 | 0.81 | CES2 (0.65) | CES2GAAP2RX1MEN1KMT2A | |
| SCHEMBL23341243 | 0.81 | CES2 (0.68) | CES2NOTUMGAAMAPTRXRA | |
| SCHEMBL10986357 | 0.79 | CES2 (0.59) | CES2MAPTMEN1KMT2ACES1 | |
| SCHEMBL2365619 | 0.77 | CES2 (0.50) | CES2NOTUMGAAMAPTRXRA | |
| SCHEMBL12288118 | 0.77 | CES2 (0.50) | CES2NOTUMGAAMAPTRXRA | |
| SCHEMBL8767972 | 0.76 | CES2 (0.55) | CES2GAAMAPTRXRARXRB | |
| SCHEMBL96116 | 0.76 | CES2 (0.67) | CES2NOTUMGAAMAPTRXRA | |
| SCHEMBL25658887 | 0.75 | CES2 (0.48) | CES2GAAMAPTKMT2A | |
| SCHEMBL16180051 | 0.75 | CES2 (0.73) | CES2NOTUMGAAMAPTRXRA | |
| Hydrochloric Acid SCHEMBL8503522 | 0.75 | CES2 (0.53) | CES2GAAMAPTRXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365085-B2 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-29 | — | — | US | disclosed |
| EP-1575495-A2 | COMPOUNDS AND METHODS | SmithKline Beecham Corporation (US) | 2005-09-21 | — | — | EP | disclosed |
| US-20050113580-A1 | Amide compounds and methods of using the same | SMITHKLINE BEECHAM CORP | 2005-05-26 | — | — | US | disclosed |
| WO-2003082205-A2 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
| US-4528379-A | Preparation of substituted thiadiazolyloxyacetamides | BAYER AKTIENGESELLSCHAFT (DE) | 1985-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113580-A1 | Amide compounds and methods of using the same | NR1H2, NR1H3, PPARA | CES2 511/4885NOTUM 154/4885GAA 1405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.